Press Releases

Year

Aug 11, 2021

Vaxcyte Reports Second Quarter 2021 Financial Results and Provides Business Update

FOSTER CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today

Additional Formats

PDF Version

Aug 05, 2021

Vaxcyte Announces Expanded CARB-X Award to Advance Development of VAX-A1, a Vaccine to Prevent Group A Streptococcus Infections

-- Award Commits an Additional $3.2 Million in Funding; Total Potential Funding of $29.7 Million Based on Future Milestones -- -- Vaxcyte Plans to Initiate IND-Enabling Studies for VAX-A1 in Second Half of 2021 -- FOSTER CITY, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc.

Additional Formats

PDF Version

May 27, 2021

Vaxcyte to Present at the Jefferies Virtual Healthcare Conference

FOSTER CITY, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today

Additional Formats

PDF Version

May 11, 2021

Vaxcyte Reports First Quarter 2021 Financial Results and Provides Business Update

FOSTER CITY, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today

Additional Formats

PDF Version

May 10, 2021

Vaxcyte Announces Publication of Preclinical Data Supporting the Potential of VAX-24 for the Prevention of Invasive Pneumococcal Disease

VAX-24 is a 24-Valent Broad-Spectrum Pneumococcal Conjugate Vaccine Leveraging Vaxcyte’s Technology Platform FOSTER CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel

Additional Formats

PDF Version

May 06, 2021

Vaxcyte to Present at BofA Securities 2021 Health Care Conference

FOSTER CITY, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today

Additional Formats

PDF Version

Apr 05, 2021

Vaxcyte to Present at 20th Annual Needham Virtual Healthcare Conference

FOSTER CITY, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today

Additional Formats

PDF Version

Mar 29, 2021

Vaxcyte Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

FOSTER CITY, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today

Additional Formats

PDF Version

Mar 22, 2021

Vaxcyte to Report Fourth Quarter and Full Year 2020 Financial Results on March 29, 2021

FOSTER CITY, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today

Additional Formats

PDF Version

Jan 06, 2021

Vaxcyte Announces Publication of Preclinical Proof-of-Concept Data Supporting Potential of VAX-A1, a Novel Conjugate Vaccine Designed to Prevent Group A Strep Infections

FOSTER CITY, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the

Additional Formats

PDF Version